

## Grifols and partners working together on Plasbumin® for China

Grifols and its partners Anhui Tonrol and Shanghai RAAS (SRAAS) have very good reason to celebrate: the introduction of a new albumin brand in China, Plasbumin®.

At the Plasbumin® introduction held in Shanghai in July 2021, more than 100 industry leaders, including representatives of major distribution companies, logistic partners and industry experts were on hand to hear about the product and the long-term vision that the strategic alliance between Grifols and SRAAS has for China's blood products industry.

It's important to note that China is the largest albumin market worldwide, accounting for more than 40% of total albumin consumption. The country's demand has been growing significantly in recent years and is expected to keep increasing in the near future, driven by efforts to expand healthcare access, GDP per capita growth, the aging of the population, and new evidence supporting albumin's clinical value.

With Plasbumin®, which is Grifols' third albumin brand for China, the company reinforces its commitment to enhancing the procurement of this vital plasma protein. Just like Human Albumin Grifols and Albutein®, Plasbumin® is produced under very high safety and quality standards. A unique and historical brand that was first registered in the U.S. back in 1942, it is produced at Grifols' state-of-the-art facilities in Clayton, North Carolina (U.S.), one of the largest plasma-derived medicine manufacturing sites in the world, with a fractionation capacity of 10 million liters yearly. These facilities are approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Plasma Protein Therapeutics Association (PPTA). The installations have received "Zero Waste To Landfill" gold certification as part of Grifols' commitment to environmental sustainability.

Grifols remains committed to supporting Chinese patients as well as contributing to the development of China's healthcare system, continuing a history of almost 40 years in the country. In fact, Grifols Human Albumin was one of the first imported albumin products registered by the China Food and Drug Administration (CFDA) in 1988. A few years later, Albutein® was launched and since then Grifols has been steadily increasing the supply to China to support the market as much as possible. Throughout the years, and collaboratively through its partners, Grifols has achieved a leadership position in China's albumin market, particularly in the hospital channel.

In the context of the strategic alliance between Grifols and SRAAS, Grifols and Anhui Tonrol (company belonging to the SRAAS group) will jointly launch Plasbumin® through a new integrated commercial platform. This platform, with 500+ commercial partners and direct sales, will now have full geographical reach, extensive coverage and an expanded customer base. With the addition of Plasbumin®, Grifols and SRAAS/Tonrol will have the broadest albumin portfolio in China, which will contribute to meeting the growing needs of Chinese doctors and patients across the country.

With this new robust commercial platform and Plasbumin®, Grifols and SRAAS together envision a brighter future not only for China's albumin market but also for the whole blood products industry.